Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case with high viral load.. 96% Improvement Relative Risk Case 72% primary Desort-Henin et al. NCT05305560 SAIVE Ivermectin RCT Prophylaxis Does ivermectin reduce COVID-19 infections? Double-blind RCT 399 patients in Bulgaria (March - October 2022) Fewer cases with ivermectin (p<0.000001) Desort-Henin et al., ECCMID 2023 Favors ivermectin Favors control

The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results

Desort-Henin et al., ECCMID 2023 (results released 1/5/2023) (Preprint), SAIVE, NCT05305560 (history)
Desort-Henin et al., The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results, ECCMID 2023 (results released 1/5/2023) (Preprint), SAIVE, NCT05305560
Jan 2023   Source   PDF  
  All Studies   Meta
PEP RCT 399 patients in Bulgaria showing significantly lower COVID-19 cases with ivermectin prophylaxis, and significantly lower cases with high viral load. No participant had severe symptoms, required oxygen, or was hospitalized. All patients with COVID-19 were treated with vitamin C and vitamin D.
This trial makes the Cochrane analysis report statistically significant efficacy for prophylaxis, although they do not appear to have acknowledged this yet. There are currently 4 prophylaxis RCTs, and all 4 show statistically significant efficacy of ivermectin. Cochrane ignored them by simply choosing to only include post-exposure prophylaxis RCTs, even though they were included for the paxlovid analysis with many of the same authors. At the time there were no post-exposure RCTs and they knew that including any one of the 3 pre-exposure prophylaxis RCTs would show statistically significant efficacy.
This is the 45th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 95th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of case with high viral load, 96.0% lower, RR 0.04, p < 0.001, treatment 4 of 200 (2.0%), control 99 of 199 (49.7%), NNT 2.1.
risk of case, 71.6% lower, RR 0.28, p < 0.001, treatment 30 of 200 (15.0%), control 105 of 199 (52.8%), NNT 2.6, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Desort-Henin et al., 5 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Bulgaria, preprint, 5 authors, study period March 2022 - October 2022, dosage 200μg/kg day 1, 100μg/kg days 2-28, trial NCT05305560 (history) (SAIVE).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
AI generated summary. Current AI models can provide useful summaries for non-experts, but may be inaccurate and have limited ability to analyze larger context such as the entire evidence base for ivermectin.
  • A randomized, double-blind, placebo-controlled trial found that ivermectin reduced the risk of infection following exposure to SARS-CoV-2 by 72%.
  • Ivermectin was also shown to be safe in doses and duration higher than currently used in approved indications.


Ivermectin (IVM) is currently used to treat several parasitic diseases and has a proven safety profile over many decades of exposure. It is one of the several drugs explored for its potential therapeutic and preventive role against SARS-CoV-2 infection. Previous studies had reported its antiviral effects on both RNA and DNA viruses. Caly et al. demonstrated that a single dose of IVM could control the in vitro replication of SARS-CoV-2. Several mechanisms of action have been suggested for its effect on SARS-CoV-2. Those mechanisms could lead to an efficient SARS-CoV-2 prevention, independently of virus mutations. Post-exposure prophylaxis (PEP) is a method of preventing SARS-CoV-2 infection after a known exposure to the virus that may limit the spread of infection.


The SAIVE Trial (NCT05305560) is a randomized, double blind, multicenter, parallel group, placebo-controlled clinical trial, assessing the efficacy and safety of ivermectin in a post-exposure population, conducted in 11 clinical sites in Bulgaria between March and Oct. 2022. The primary objective of the SAIVE trial was to evaluate the efficacy of a continuous administration of oral ivermectin as post-exposure prophylaxis against SARS-CoV-2 infection in confirmed contact cases. Additionally, this study would further reinforce the safety of continuous exposure to ivermectin, as evaluated in a previous phase 1 study (NCT04632706). Out of 400 enrolled, 399 participants were randomized in a 1/1 ratio to ivermectin or matching placebo. Main inclusion criteria was confirmed contact within 5 days with a positive COVID-19 case (assessed by RT-PCR). Primary endpoint was the proportion of confirmed infections between groups from baseline to day 28.


This study demonstrated highly statistically significant evidence in a large, randomized, double-blind, placebo-controlled study that daily oral treatment with ivermectin reduced the risk of infection following exposure to SARS-CoV-2. Ivermectin was also shown to be safe in doses and duration higher than currently used in approved indications.


Ivermectin demonstrated a significant efficacy in preventing COVID-19 infection in a post exposure setting as compared to placebo group. The lower viral loads observed with ivermectin could potentially indicate a lower risk of disease severity and a lower contagiousness. We can hypothesize that ivermectin would be a valuable tool in the protection of at-risk populations, in addition to vaccination. Efficacy of ivermectin administration was similar regardless of the subvariant during the trial (60% of infections were related to Omicron BA.5 and 40% to BA.1.1) and the significance of results is equivalent to overall RRR on the whole population in both subgroups.

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop